Milestone Pharmaceuticals Stock Total Debt
| MIST Stock | USD 1.54 0.01 0.65% |
Milestone Pharmaceuticals fundamentals help investors to digest information that contributes to Milestone Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Milestone Stock. The fundamental analysis module provides a way to measure Milestone Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Milestone Pharmaceuticals stock.
Total Debt To Capitalization is likely to gain to 0.79 in 2024. Milestone | Total Debt |
Milestone Pharmaceuticals Company Total Debt Analysis
Milestone Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Milestone Pharmaceuticals Total Debt | 51.77 M |
Most of Milestone Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Milestone Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Milestone Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Milestone Pharmaceuticals is extremely important. It helps to project a fair market value of Milestone Stock properly, considering its historical fundamentals such as Total Debt. Since Milestone Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Milestone Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Milestone Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Milestone Total Debt Historical Pattern
Today, most investors in Milestone Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Milestone Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Milestone Pharmaceuticals total debt as a starting point in their analysis.
Milestone Pharmaceuticals Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Milestone Net Debt
Net Debt |
|
Based on the latest financial disclosure, Milestone Pharmaceuticals has a Total Debt of 51.77 M. This is 98.12% lower than that of the Pharmaceuticals sector and 84.06% lower than that of the Health Care industry. The total debt for all United States stocks is 99.03% higher than that of the company.
Milestone Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Milestone Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Milestone Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Milestone Pharmaceuticals by comparing valuation metrics of similar companies.Milestone Pharmaceuticals is currently under evaluation in total debt category among its peers.
Milestone Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Milestone Pharmaceuticals from analyzing Milestone Pharmaceuticals' financial statements. These drivers represent accounts that assess Milestone Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Milestone Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 252.7M | 196.6M | 274.0M | 168.1M | 71.7M | 68.1M | |
| Enterprise Value | 133.4M | 125.2M | 160.6M | 163.0M | 109.8M | 207.7M |
Milestone Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Milestone Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Milestone Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Milestone Pharmaceuticals' value.| Shares | Bml Capital Management Llc | 2024-06-30 | 1.1 M | Altium Capital Management, Lp | 2024-06-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 828.7 K | Ikarian Capital, Llc | 2024-06-30 | 466 K | Boxer Capital Llc | 2024-06-30 | 309 K | Adar1 Capital Management Llc | 2024-06-30 | 202.5 K | Ancora Advisors Llc | 2024-06-30 | 60 K | Envestnet Asset Management Inc | 2024-06-30 | 59.5 K | Squarepoint Ops Llc | 2024-06-30 | 54.7 K | Blackrock Inc | 2024-06-30 | 5 M | Nantahala Capital Management, Llc | 2024-06-30 | 3.5 M |
Milestone Fundamentals
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 52.3 M | ||||
| Shares Outstanding | 53.27 M | ||||
| Shares Owned By Insiders | 0.69 % | ||||
| Shares Owned By Institutions | 56.91 % | ||||
| Number Of Shares Shorted | 382.56 K | ||||
| Price To Earning | (4.44) X | ||||
| Price To Book | 2.57 X | ||||
| Price To Sales | 91.95 X | ||||
| Revenue | 1000 K | ||||
| Gross Profit | 5 M | ||||
| EBITDA | (60.81 M) | ||||
| Net Income | (59.69 M) | ||||
| Cash And Equivalents | 86.24 M | ||||
| Cash Per Share | 2.87 X | ||||
| Total Debt | 51.77 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.26 X | ||||
| Book Value Per Share | 0.48 X | ||||
| Cash Flow From Operations | (46.42 M) | ||||
| Short Ratio | 3.80 X | ||||
| Earnings Per Share | (1.01) X | ||||
| Target Price | 10.25 | ||||
| Number Of Employees | 47 | ||||
| Beta | 1.72 | ||||
| Market Capitalization | 81.77 M | ||||
| Total Asset | 75.23 M | ||||
| Retained Earnings | (326.03 M) | ||||
| Working Capital | 65.81 M | ||||
| Current Asset | 110.42 M | ||||
| Current Liabilities | 7.17 M | ||||
| Net Asset | 75.23 M |
About Milestone Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Milestone Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Milestone Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Milestone Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.